Evidence map›Paper›PMID 30410673›Full record

ArticleOncotarget2018

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant

Liu Lu, Chung Hoow Kok, Verity Ann Saunders, Jueqiong Wang, Jennifer Anne McLean, Timothy Peter Hughes, Deborah Lee White

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Liu LuSouth Australian Health and Medical Research Institute (SAHMRI), Cancer Theme, Adelaide, SA, Australia.
Chung Hoow KokSouth Australian Health and Medical Research Institute (SAHMRI), Cancer Theme, Adelaide, SA, Australia.
Verity Ann SaundersSouth Australian Health and Medical Research Institute (SAHMRI), Cancer Theme, Adelaide, SA, Australia.
Jueqiong WangAustralian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Jennifer Anne McLeanSouth Australian Health and Medical Research Institute (SAHMRI), Cancer Theme, Adelaide, SA, Australia.
Timothy Peter HughesSouth Australian Health and Medical Research Institute (SAHMRI), Cancer Theme, Adelaide, SA, Australia.
Deborah Lee WhiteSouth Australian Health and Medical Research Institute (SAHMRI), Cancer Theme, Adelaide, SA, Australia.
South Australian Health and Medical Research Institute · AUUniversity of Adelaide · AUAustralian Centre for HIV and Hepatitis Virology Research · AUSouth Australia Pathology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TKI resistance remains a major impediment to successful treatment of CML. In this study, we investigated the emerging modes of ponatinib resistance in TKI-naïve and dasatinib resistant

Indexed as

AxlBcr-Abl+ cell lineschronic myeloid leukaemiacompound mutationponatinib resistance

Identifiers

PMID30410673
PMCPMC6205183
OpenAlexW2894728564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.